Rosario Garcia Campelo explains that NETs account for 25% of primary lung tumours, among them a majority are poorly differentiated, high grade small-cell carcinomas. For patients with lung NETs a final diagnosis can be difficult to establish and the standard of care is still surgery, although systemic therapies such as somatostatin analogous, targeted agents are showing very good results.
For the near future, she thinks that the main challenge is the multidisciplinary approach. As our molecular knowledge of the
disease is growing, we should also explore genetical origin in these tumours. Establishing a research network for this type of cancers would help to explore the role of targeted therapies.
1) The incidence of NETs of lung origin
2) Diagnosis and clinical presentation
3) Key advances in the treatment of NETs of lung origin?
4) Future outlook
Produced by the European Society for Medical Oncology
Adding ibrutinib to treatment with CAR T-cell therapy was feasible, led to deeper remissions, and reduced the…
Internet is huge! Help us find great content